Globeflex Capital L P Sells 5,186 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Globeflex Capital L P reduced its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 8.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 54,858 shares of the biotechnology company's stock after selling 5,186 shares during the quarter. United Therapeutics accounts for about 1.6% of Globeflex Capital L P's holdings, making the stock its 13th largest holding. Globeflex Capital L P owned approximately 0.12% of United Therapeutics worth $19,356,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Milestone Asset Management LLC increased its holdings in shares of United Therapeutics by 56.5% during the fourth quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company's stock valued at $1,014,000 after acquiring an additional 1,037 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in shares of United Therapeutics by 9.1% in the fourth quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company's stock worth $3,326,000 after acquiring an additional 789 shares during the period. JPMorgan Chase & Co. increased its holdings in United Therapeutics by 35.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company's stock valued at $68,999,000 after acquiring an additional 50,291 shares during the last quarter. Burney Co. increased its position in United Therapeutics by 113.3% in the fourth quarter. Burney Co. now owns 23,922 shares of the biotechnology company's stock worth $8,441,000 after purchasing an additional 12,705 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in United Therapeutics by 97.7% during the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company's stock worth $89,532,000 after acquiring an additional 123,929 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Remove Ads

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the company's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at $929,678.52. This represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Louis W. Sullivan sold 26,209 shares of the firm's stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the transaction, the director now directly owns 5,051 shares in the company, valued at $1,885,134.22. This represents a 83.84 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 116,464 shares of company stock valued at $42,396,244. Insiders own 11.90% of the company's stock.

United Therapeutics Trading Up 5.1 %

Shares of NASDAQ:UTHR traded up $15.70 during midday trading on Monday, hitting $322.94. The stock had a trading volume of 400,448 shares, compared to its average volume of 443,935. The stock has a 50 day moving average price of $349.77 and a two-hundred day moving average price of $358.53. The company has a market capitalization of $14.50 billion, a PE ratio of 14.18, a P/E/G ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 1 year low of $221.53 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period last year, the business posted $4.36 EPS. As a group, equities analysts expect that United Therapeutics Co. will post 24.48 EPS for the current year.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research note on Thursday, February 27th. StockNews.com lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, February 27th. Finally, UBS Group raised their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, United Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.